Prospective evaluation of blood concentration of mitochondrial DNA as a marker of toxicity in 157 consecutively recruited untreated or HAART-treated HIV-positive patients

被引:46
作者
Chiappini, F
Teicher, E
Saffroy, R
Pham, P
Falissard, B
Barrier, A
Chevalier, S
Debuire, B
Vittecoq, D
Lemoine, A
机构
[1] Hop Paul Brousse, Serv Biochim & Biol Mol, INSERM 602, F-94800 Villejuif, France
[2] Univ Paris 11, Fac Med, Hop Paul Brousse, Serv Sante Publ, Villejuif, France
[3] Univ Paris 11, Fac Med, Hop Paul Brousse, Serv Infectiol, Villejuif, France
[4] PFIZER, Ctr Rech, Amboise, France
[5] Hop St Antoine, INSERM 444, F-75571 Paris, France
关键词
HAART toxicity; HIV infection; lactataemia; lipodystrophy; mitochondrial DNA; mitochondrial toxicity;
D O I
10.1038/labinvest.3700113
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Highly active antiretroviral therapy (HAART) can cause mitochondrial toxicity. The concentration of mitochondrial DNA (mtDNA) in peripheral blood cells has been reported to be a marker of this toxicity. However, these observations are controversial and were drawn from small series. Thus, we analysed the value of blood mtDNA as a marker of mitochondrial toxicity in a large cohort of human immunodeficiency virus (HIV)-infected out-patients during routine clinical evaluations. Real-time quantitative PCR was used to determine the mtDNA to nuclear DNA (nDNA) ratio in peripheral blood mononuclear cells from 157 consecutive HIV-1-infected patients (13 naive, 144 receiving HAART) and 30 HIV-1-uninfected patients. The mtDNA to nDNA ratio was significantly lower in both groups of HIV-infected patients than in the control group. No significant difference was observed between treated and naive HIV-infected patients. Lactataemia was significantly lower in controls than in the group of HIV-treated patients. None of the treated patients had lactataemia >5 mmol/l or bicarbonates <20 mmol/l. Triglyceride levels were significantly higher in the HAART-treated patients than in the nontreated patients. Clinical symptoms of lipodystrophy were observed in 62 HAART-treated patients. These symptoms were not associated with an abnormal mtDNA to nDNA ratio or plasma triglyceride concentration. The mtDNA to nDNA ratio was lower in DDI/D4T-treated patients than in AZT/3TC-treated patients. In conclusion, there are no obvious links between the mtDNA to nDNA ratio in peripheral mononuclear cells and any clinical symptoms or lactate level. Thus, the mtDNA to nDNA ratio in leukocytes does not seem to be an accurate marker of mild and/or long-term mitochondrial toxicity.
引用
收藏
页码:908 / 914
页数:7
相关论文
共 42 条
  • [1] Agreement analysis of variables involved in lipodystrophy syndrome definition in HIV-infected patients
    Belloso, WH
    Quirós, RE
    Ivalo, SA
    Perman, MI
    Galich, AM
    Stern, LD
    Barcán, LA
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 32 (01) : 104 - 111
  • [2] Tenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerases α,δ, and ε
    Birkus, G
    Hájek, M
    Kramata, P
    Votruba, I
    Holy, A
    Otová, B
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (05) : 1610 - 1613
  • [3] Metabolic acidosis in HIV-infected patients
    Bonnet, F
    Bonarek, M
    Abrij, A
    Beylot, J
    Morlat, P
    [J]. CLINICAL INFECTIOUS DISEASES, 2002, 34 (09) : 1289 - 1290
  • [4] Hyperlactatemia and antiretroviral therapy: The Swiss HIV Cohort Study
    Boubaker, K
    Flepp, M
    Sudre, P
    Furrer, H
    Haensel, A
    Hirschel, B
    Boggian, K
    Chave, JP
    Bernasconi, E
    Egger, M
    Opravil, M
    Rickenbach, M
    Francioli, P
    Telenti, A
    [J]. CLINICAL INFECTIOUS DISEASES, 2001, 33 (11) : 1931 - 1937
  • [5] Editorial response: Hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors
    Brinkman, K
    [J]. CLINICAL INFECTIOUS DISEASES, 2000, 31 (01) : 167 - 169
  • [6] Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
    Brinkman, K
    Smeitink, JA
    Romijn, JA
    Reiss, P
    [J]. LANCET, 1999, 354 (9184) : 1112 - 1115
  • [7] Management of hyperlactatemia: no need for routine lactate measurements
    Brinkman, K
    [J]. AIDS, 2001, 15 (06) : 795 - 797
  • [8] Fatal lactic acidosis and liver steatosis associated with didanosine and stavudine treatment:: a respiratory chain dysfunction?
    Brivet, FG
    Nion, I
    Mégarbane, B
    Slama, A
    Brivet, M
    Rustin, P
    Munnich, A
    [J]. JOURNAL OF HEPATOLOGY, 2000, 32 (02) : 364 - 365
  • [9] Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study
    Carr, A
    Samaras, K
    Thorisdottir, A
    Kaufmann, GR
    Chisholm, DJ
    Cooper, DA
    [J]. LANCET, 1999, 353 (9170) : 2093 - 2099
  • [10] A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome
    Carr, A
    Miller, J
    Law, M
    Cooper, DA
    [J]. AIDS, 2000, 14 (03) : F25 - F32